stoxline Quote Chart Rank Option Currency Glossary
  
MoonLake Immunotherapeutics (MLTX)
41.7  0.85 (2.08%)    05-28 16:00
Open: 41.14
High: 41.75
Volume: 241,339
  
Pre. Close: 40.85
Low: 40.0525
Market Cap: 2,622(M)
Technical analysis
2024-05-28 4:54:26 PM
Short term     
Mid term     
Targets 6-month :  53.21 1-year :  62.15
Resists First :  45.56 Second :  53.21
Pivot price 40.87
Supports First :  40.78 Second :  37.83
MAs MA(5) :  40.29 MA(20) :  41.45
MA(100) :  49.54 MA(250) :  50.03
MACD MACD :  -1.1 Signal :  -1.3
%K %D K(14,3) :  41.9 D(3) :  32.1
RSI RSI(14): 48.8
52-week High :  64.98 Low :  24.3
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MLTX ] has closed below upper band by 33.9%. Bollinger Bands are 44.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 41.78 - 41.9 41.9 - 42.04
Low: 39.68 - 39.83 39.83 - 40
Close: 41.43 - 41.66 41.66 - 41.92
Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Headline News

Sun, 26 May 2024
Westfield Capital Management Co. LP Boosts Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Fri, 24 May 2024
Why MoonLake (MLTX) Might Surprise This Earnings Season - Yahoo Movies Canada

Wed, 22 May 2024
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 7% - MarketBeat

Tue, 21 May 2024
Wedbush Reiterates MoonLake Immunotherapeutics - (MLTX) Outperform Recommendation - MSN

Tue, 14 May 2024
Victory Capital Management Inc. Cuts Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Tue, 14 May 2024
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 63 (M)
Shares Float 23 (M)
Held by Insiders 9.4 (%)
Held by Institutions 96.7 (%)
Shares Short 7,260 (K)
Shares Short P.Month 7,000 (K)
Stock Financials
EPS -0.74
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.19
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -11.3 %
Return on Equity (ttm) -15.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.87
Qtrly Earnings Growth 0 %
Operating Cash Flow -43 (M)
Levered Free Cash Flow -25 (M)
Stock Valuations
PE Ratio -57.13
PEG Ratio 0
Price to Book value 5.08
Price to Sales 0
Price to Cash Flow -61.29
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android